Serelaxin-mediated signal transduction in human vascular cells: Bell-shaped concentration-response curves reflect differential coupling to G proteins

British Journal of Pharmacology

Volumn 172, Issue 4, 2015, Pages 1005-1019

  Sarwar, M ^a   Samuel, C S ^a   Bathgate, R A ^b   Stewart, D R ^c   Summers, R J ^a  

^a MONASH UNIVERSITY   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c Florey Institute of Neuroscience and Mental Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC GMP; ET BETA RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA I O SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA S SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEURONAL NITRIC OXIDE SYNTHASE; RECEPTOR; RXFP1 RECEPTOR; SERELAXIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ENDOTHELIN B RECEPTOR; G PROTEIN COUPLED RECEPTOR; GELATINASE A; GELATINASE B; GUANINE NUCLEOTIDE BINDING PROTEIN; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; RECOMBINANT PROTEIN; RELAXIN; RXFP1 PROTEIN, HUMAN; SERELAXIN PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTERY MUSCLE; ARTICLE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FETUS; FIBROBLAST; HUMAN; HUMAN CELL; LIPID RAFT; LONG TERM EXPOSURE; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UMBILICAL VEIN ENDOTHELIAL CELL; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; SMOOTH MUSCLE CELL; UMBILICAL ARTERY; UMBILICAL VEIN;

CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FIBROBLASTS; GTP-BINDING PROTEINS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE SYNTHASE TYPE I; RECEPTOR, ENDOTHELIN B; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RECOMBINANT PROTEINS; RELAXIN; SIGNAL TRANSDUCTION; UMBILICAL ARTERIES; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84921792573     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12964     Document Type: Article

References (57)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ligand-gated ion channels. Br J Pharmacol 170: 1582-1606.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Alexiou K, Wilbring M, Matschke K, Dschietzig T (2013). Relaxin protects rat lungs from ischemia-reperfusion injury via inducible NO synthase: role of ERK-1/2, PI3K, and forkhead transcription factor FKHRL1. PLoS ONE 8: e75592.
5. Baker JG, Hill SJ (2006). A comparison of the antagonist affinities for the Gi- and Gs-coupled states of the human adenosine A1-receptor. J Pharmacol Exp Ther 320: 218-228.
6. Bani D, Failli P, Bello MG, Thiemermann C, Bani Sacchi T, Bigazzi M et al. (1998a). Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture. Hypertension 31: 1240-1247.
7. Bani D, Masini E, Bello MG, Bigazzi M, Sacchi TB (1998b). Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart. Am J Pathol 152: 1367-1376.
8. Boulanger CM, Heymes C, Benessiano J, Geske RS, Lévy BI, Vanhoutte PM (1998). Neuronal nitric oxide synthase is expressed in rat vascular smooth muscle cells: activation by angiotensin II in hypertension. Circ Res 83: 1271-1278.
9. Bruzzone A, Saulière A, Finana F, Sénard J-M, Lüthy I, Galés C (2014). Dosage-dependent regulation of cell proliferation and adhesion through dual β2-adrenergic receptor/cAMP signals. FASEB J 28: 1342-1354.
10. Buchwalow IB, Podzuweit T, Böcker W, Samoilova VE, Thomas S, Wellner M et al. (2002). Vascular smooth muscle and nitric oxide synthase. FASEB J 16: 500-508.
11. Chow BSM, Chew EGY, Zhao C, Bathgate RAD, Hewitson TD, Samuel CS (2012). Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. PLoS ONE 7: e42714.
12. Conrad KP (2010). Unveiling the vasodilatory actions and mechanisms of relaxin. Hypertension 56: 2-9.
13. Conrad KP, Shroff SG (2011). Effects of relaxin on arterial dilation, remodeling, and mechanical properties. Curr Hypertens Rep 13: 409-420.
14. Conrad KP, Debrah DO, Novak J, Danielson LA, Shroff SG (2004). Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats. Endocrinology 145: 3289-3296.
15. Danielson L, Conrad KP (2003). Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats. J Appl Physiol 95: 1509-1514.
16. Debrah DO, Novak J, Matthews JE, Ramirez RJ, Shroff SG, Conrad KP (2006). Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats. Endocrinology 147: 5126-5131.
17. Dschietzig T, Bartsch C, Richter C, Laule M, Baumann G, Stangl K (2003). Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res 92: 32-40.
18. Dschietzig T, Alexiou K, Kinkel H-T, Baumann G, Matschke K, Stangl K (2011). The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of G(i)-phosphoinositide-3 kinase signaling. J Card Fail 17: 158-166.
19. Dulak J, Józkowicz A, Dembinska-Kiec A, Guevara I, Zdzienicka A, Zmudzinska-Grochot D et al. (2000). Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 20: 659-666.
20. Fernandez-Patron C, Radomski MW, Davidge ST (1999). Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85: 906-911.
21. Ferrara N (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
22. Halls ML, Bond CP, Sudo S, Kumagai J, Ferraro T, Layfield S et al. (2005). Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8). J Pharmacol Exp Ther 313: 677-687.
23. Halls ML, Bathgate RAD, Summers RJ (2006). Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms. Mol Pharmacol 70: 214-226.
24. Halls ML, van der Westhuizen ET, Wade JD, Evans BA, Bathgate RAD, Summers RJ (2009a). Relaxin Family Peptide Receptor (RXFP1) Coupling to Gαi3 Involves the C-Terminal Arg752 and localization within membrane raft microdomains. Mol Pharmacol 75: 415-428.
25. Halls ML, Hewitson TD, Moore X-L, Du X-J, Bathgate RAD, Summers RJ (2009b). Relaxin activates multiple cAMP signaling pathway profiles in different target cells. Ann N Y Acad Sci 1160: 108-111.
26. Ichihara A, Inscho EW, Imig JD, Navar LG (1998). Neuronal nitric oxide synthase modulates rat renal microvascular function. Am J Physiol 274: F516-F524.
27. Jelinic M, Leo C-H, Post Uiterweer ED, Sandow SL, Gooi JH, Wlodek ME et al. (2014). Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment. FASEB J 28: 275-287.
28. Jeyabalan A, Novak JJ, Danielson LA, Kerchner LJ, Opett SL, Conrad KP (2003). Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ Res 93: 1249-1257.
29. Jeyabalan A, Kerchner LJ, Fisher MC, McGuane JT, Doty KD, Conrad KP (2006a). Matrix metalloproteinase-2 activity, protein, mRNA, and tissue inhibitors in small arteries from pregnant and relaxin-treated nonpregnant rats. J Appl Physiol 100: 1955-1963.
30. Jeyabalan A, Novak J, Doty KD, Matthews J, Fisher MC, Kerchner LJ et al. (2006b). Vascular matrix metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short-term administration of relaxin. Endocrinology 148: 189-197.
31. Kavdia M (2004). Contribution of nNOS- and eNOS-derived NO to microvascular smooth muscle NO exposure. J Appl Physiol 97: 293-301.
32. Li Y, Brookes ZL, Kaufman S (2005). Acute and chronic effects of relaxin on vasoactivity, myogenic reactivity and compliance of the rat mesenteric arterial and venous vasculature. Regul Pept 132: 41-46.
33. Masini E, Bani D, Bello MG, Bigazzi M, Mannaioni PF, Sacchi TB (1997). Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide. Endocrinology 138: 4713-4720.
34. Masini E, Cuzzocrea S, Mazzon E, Muià C, Vannacci A, Fabrizi F et al. (2006). Protective effects of relaxin in ischemia/reperfusion-induced intestinal injury due to splanchnic artery occlusion. Br J Pharmacol 148: 1124-1132.
35. McGuane JT, Danielson LA, Debrah JE, Rubin JP, Novak J, Conrad KP (2011a). Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension 57: 1151-1160.
36. McGuane JT, Debrah JE, Sautina L, Jarajapu YPR, Novak J, Rubin JP et al. (2011b). Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 152: 2786-2796.
37. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH et al. (2013). Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61: 196-206.
38. Milanini J, Viñals F, Pouysségur J, Pagès G (1998). p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 273: 18165-18172.
39. Mohaupt MG, Elzie JL, Ahn KY, Clapp WL, Wilcox CS, Kone BC (1994). Differential expression and induction of mRNAs encoding two inducible nitric oxide synthases in rat kidney. Kidney Int 46: 653-665.
40. Mookerjee I, Hewitson TD, Halls ML, Summers RJ, Mathai ML, Bathgate RAD et al. (2009). Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J 23: 1219-1229.
41. Mosterd A, Hoes AW (2007). Clinical epidemiology of heart failure. Heart 93: 1137-1146.
42. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
43. Quattrone S, Chiappini L, Scapagnini G, Bigazzi B, Bani D (2004). Relaxin potentiates the expression of inducible nitric oxide synthase by endothelial cells from human umbilical vein in in vitro culture. Mol Hum Reprod 10: 325-330.
44. Rettinger J, Braun K, Hochmann H, Kassack MU, Ullmann H, Nickel P et al. (2005). Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist. Neuropharmacology 48: 461-468.
45. Samuel CS, Unemori EN, Mookerjee I, Bathgate RAD, Layfield SL, Mak J et al. (2004). Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 145: 4125-4133.
46. Soto F, Lambrecht G, Nickel P, Stühmer W, Busch AE (1999). Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors. Neuropharmacology 38: 141-149.
47. Spurway J, Logan P, Pak S (2012). The development, structure and blood flow within the umbilical cord with particular reference to the venous system. Aust J Ultrasound Med 15: 97-102.
48. Sun Y, Huang J, Xiang Y, Bastepe M, Jüppner H, Kobilka BK et al. (2007). Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J 26: 53-64.
49. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD et al. (2009). Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373: 1429-1439.
50. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH et al. (2013). Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381: 29-39.
51. Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME et al. (1996). Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 98: 2739-2745.
52. Unemori EN, Lewis M, Constant J, Arnold G, Grove BH, Normand J et al. (2000). Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen 8: 361-370.
53. van der Westhuizen ET, Werry TD, Sexton PM, Summers RJ (2007). The relaxin family peptide receptor 3 activates extracellular signal-regulated kinase 1/2 through a protein kinase C-dependent mechanism. Mol Pharmacol 71: 1618-1629.
54. van der Westhuizen ET, Christopoulos A, Sexton PM, Wade JD, Summers RJ (2010). H2 relaxin is a biased ligand relative to H3 relaxin at the relaxin family peptide receptor 3 (RXFP3). Mol Pharmacol 77: 759-772.
55. Xu KY, Huso DL, Dawson TM, Bredt DS, Becker LC (1999). Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc Natl Acad Sci U S A 96: 657-662.
56. Xu Q, Chakravorty A, Bathgate RAD, Dart AM, Du X-J (2010). Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats. Hypertension 55: 1260-1266.
57. Zhang Q, Liu S-H, Erikson M, Lewis M, Unemori E (2002). Relaxin activates the MAP kinase pathway in human endometrial stromal cells. J Cell Biochem 85: 536-544.